The process of cognition includes a wide array of brain functions. These include: working memory, inhibition of interfering stimuli, short-term recall, memory storage, long-term memory, problem-solving, sorting and planning, internal organization of visual and spatial events, temporal organization of behaviour, reasoning, speed of perception, alertness, and ability to understand numbers and words.


Decision Resources, a research firm for pharmaceutical issues, has predicted that the market for cognitive dysfunction pharmaceutical drugs will grow to $3.7 billion per year in sales in 2016. BCC Research, a market forecasting firm, has predicted the market to reach $7.1 billion in 2014.

Clera approach

Cognition occurs in various brain regions, notably the frontal lobes, the hippocampal regions, and the basal ganglia (especially the caudate nucleus and the putamen). All of these regions contain various amounts of dopamine type 2 receptors. All of these dopamine receptors can be made more sensitive to the neurotransmitter dopamine, thereby improving the amount and speed of neurotransmission. The administration of CLR3001, a Phase II compound which is a repurposing and reformulation of a generic compound for a different central nervous system disorder, is a simple and effective way of making the dopamine type 2 receptors more sensitive to dopamine.